ERBB2 and breast carcinoma: This association has been observed in proteomic studies using other preclinical models (breast cancer patient-derived xenografts) (Huang et al., 2017) and in human cancers, with lapatinib already an approved drug used in the treatment of HER2-positive breast cancers (Xu et al., 2017).